Dynamic Changes in Liver Stiffness Measured by Transient Elastography Predict Clinical Outcomes Among Patients With Chronic Hepatitis B

Zeng, Jianyong; Cai, Sanjun; Liu, Jiajun; Xue, Xiulan; Wu, Xiaolu; Zheng, Caixia

doi:10.7863/ultra.15.12054

Cited by 39 publications

(32 citation statements)

References 26 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, several published studies evaluated the association of longitudinal LSM and clinical outcomes in patients with HBV . Li ZQ et aldemonstrated predictive factors of HCC in CHB patients with antiviral treatment, but only baseline LSM was considered.…”

Section: Discussionmentioning

confidence: 99%

On‐treatment changes of liver stiffness at week 26 could predict 2‐year clinical outcomes in HBV‐related compensated cirrhosis

Kong

Piao

et al. 2017

Liver International

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

On‐treatment changes of liver stiffness at week 26 could predict 2‐year clinical outcomes in HBV‐related compensated cirrhosis

Kong

Piao

et al. 2017

Liver International

View full text Add to dashboard Cite

show abstract

“…Transient elastography with CAP is a Food and Drug Administration (FDA)-approved modality for the diagnosis and assessment of the severity of HS, which was performed using FibroScan® (Echosens, Paris, France) by experienced operators in this study (23). Results were considered valid only for transient elastography with at least ten successful shots, a successful rate of 60% or higher, and an interquartile median ratio of less than 30%.…”

Section: Cap Assessmentmentioning

confidence: 99%

Lipid accumulation product independently correlate with hepatic steatosis quantified by controlled attenuation parameter in women with polycystic ovary syndrome

Zheng

Tong

Dong

et al. 2020

Endocrine Connections

View full text Add to dashboard Cite

Objective To explore the independent associations of the new adiposity indices lipid accumulation product (LAP) index, visceral adiposity index (VAI), and product of triglycerides and glucose (TyG) with the risks of hepatic steatosis (HS) in women with polycystic ovary syndrome (PCOS). Design This is a cross-sectional study with 101 women with PCOS undergoing controlled attenuation parameter (CAP) measurement who were recruited from November 2018 to August 2019. Multivariable logistic regression analysis was performed to determine the associations of adiposity indices with HS. Result(s) Among the 101 PCOS patients, the prevalence rate of HS was 70.3%. The PCOS patients with HS have higher percentage of overweight/obesity status, higher level of aminotransferase (AST and ALT), homeostasis model assessment of insulin resistance (HOMA-IR), LAP, VAI, TyG, waist circumference (WC), and BMI (P < 0.05). Partial correlation analysis showed LAP, WC and BMI were significantly positively associated with CAP (P < 0.05) after controlling for confounding factors. Besides, BMI, WC, and CAP were gradually elevated with the increase of LAP level. Further, multivariable logistic regression analysis showed adjusted odd ratio (OR) with associated 95% CI (OR (95% CI)) were respectively 1.09 (1.03–1.16) for LAP, 1.14 (1.05–1.23) for WC, 1.28 (1.08–1.51) for BMI, respectively. Conclusions The present study demonstrates that in women with PCOS, except for the traditional adiposity indices (WC and BMI), LAP is independently correlated with the risk of HS.

show abstract

“…34 In another study of patients with CHB, both the fibrosis index and ASTto-platelet ratio were shown to be able to predict substantial fibrosis. 35 Another study conducted by Zeng et al 36 found that FibroScan could predict the clinical outcome among patients with CHB. However, whether the AST-to-platelet ratio could predict a histologic response as effectively as FibroScan remained unknown.…”

Section: Discussionmentioning

confidence: 99%

Dynamic Changes of the Aspartate Aminotransferase‐to‐Platelet Ratio and Transient Elastography in Predicting a Histologic Response in Patients With Chronic Hepatitis B After Entecavir Treatment

Sun

et al. 2018

J of Ultrasound Medicine

View full text Add to dashboard Cite

Objectives To evaluate the dynamic changes of the aspartate aminotransferase (AST)‐to‐platelet ratio and transient elastography (FibroScan; Echosens, Paris, France) in predicting a histologic response in patients with chronic hepatitis B (CHB) after entecavir treatment. Methods A total of 148 patients with CHB were enrolled. Patient information was collected. All patients received liver biopsy and FibroScan before and after 96 weeks of entecavir treatment. Results Baseline liver biopsy results showed that there were 7 patients without liver fibrosis (fibrosis stage F0; 4.7%), 51 patients with mild liver fibrosis (F1; 34.5%), and 90 patients with advanced liver fibrosis (>F1; 60.9%). The liver stiffness value and AST‐to‐platelet ratio increased significantly as the METAVIR score of the patients increased from F0 to F4 (P < .001). After antiviral therapy for 96 weeks, the average liver stiffness value measured by FibroScan and the AST‐to‐platelet ratio showed a significant decrease. When we use a decreased liver stiffness value to predict a histologic response, the area under the receiver operating characteristic curve was 0.70 (95% confidence interval, 0.61–0.79; P < .001), and the sensitivity and specificity were 74.3% and 68.8%, respectively. The decrease of the AST‐to‐platelet ratio also could predict the histologic response of patients with CHB; the area under the receiver operating characteristic curve was 0.77 (95% confidence interval, 0.69–0.86; P < .001) with sensitivity of 76.2% and specificity of 70.2%. A multivariate analysis indicated that a high hepatitis B virus DNA viral load (odds ratio, 1.44; P = .04) and high METAVIR score (odds ratio, 1.38; P = .02) were independent risk factors for the histologic response. Conclusions Both the AST‐to‐platelet ratio and FibroScan value can effectively predict a histologic response in patients with CHB during entecavir treatment. Therefore, they can be used to monitor these patients during antiviral treatment to avoid multiple liver biopsies.

show abstract

Dynamic Changes in Liver Stiffness Measured by Transient Elastography Predict Clinical Outcomes Among Patients With Chronic Hepatitis B

Abstract: Our findings suggest that transient elastography is an effective measurement tool for diagnosing and monitoring the histologic response in patients with chronic hepatitis B during antiviral treatment and can help avoid multiple liver biopsies.

Cited by 39 publications

References 26 publications

On‐treatment changes of liver stiffness at week 26 could predict 2‐year clinical outcomes in HBV‐related compensated cirrhosis

On‐treatment changes of liver stiffness at week 26 could predict 2‐year clinical outcomes in HBV‐related compensated cirrhosis

Lipid accumulation product independently correlate with hepatic steatosis quantified by controlled attenuation parameter in women with polycystic ovary syndrome

Dynamic Changes of the Aspartate Aminotransferase‐to‐Platelet Ratio and Transient Elastography in Predicting a Histologic Response in Patients With Chronic Hepatitis B After Entecavir Treatment

Contact Info

Product

Resources

About